Immunosenescence Correlates with Poor Outcome from PD-(L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Ferrara, R. [1 ]
Naigeon, M. [2 ]
Auclin, E. [3 ]
Duchemann, B. [2 ]
Cassard, L. [2 ]
Medhi, J. J. [2 ]
Boselli, L. [2 ]
Grivel, J. [2 ]
Desnoyer, A. [2 ]
Texier, M. [2 ]
Mezquita, L. [2 ]
Aboubakar, F. [2 ]
Hendriks, L. [4 ]
Planchard, D. [2 ]
Caramella, C. [5 ]
Remon, J. [6 ]
Ngocamus, M. [2 ]
Nicotra, C. [2 ]
Proto, C. [1 ]
Sangaletti, S. [7 ]
Chaput, N. [2 ]
Besse, B. [2 ]
机构：
[1] Fdn Irccs Ist Nazl Tumori Milan, Thorac Oncol Unit, Milan, Italy
[2] Gustave Roussy, Villejuif, France
[3] Hop Europeen Georges Pompidou, Paris, France
[4] Gustave Roussy, Oncol, Villejuif, France
[5] Gustave Roussy Canc Campus, Dept Radiol, Villejuif, France
[6] Hosp Hm Delfos, Barcelona, Spain
[7] Fdn Irccs Ist Nazl Tumori, Milan, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Immunecheckpoint blockade; immunosenescence; NSCLC;
D O I：
10.1016/j.jtho.2019.08.934
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-31
引用
收藏
页码：S452 / S452
页数：1
相关论文
共 50 条
  • [1] Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients
    Ferrara, R.
    Naigeon, M.
    Auclin, E.
    Duchemann, B.
    Cassard, L.
    Medhi, J.
    Boselli, L.
    Grivel, J.
    Desnoyer, A.
    Mezquita, L.
    Nana, F. Aboubakar
    Hendriks, L.
    Planchard, D.
    Caramella, C.
    Remon, J.
    Ngocamus, M.
    Nicotra, C.
    Besse, B.
    Chaput, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S466 - S467
  • [2] ACQUIRED RESISTANCE TO PD-(L)1 BLOCKADE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Ricciuti, Biagio
    Lamberti, Giuseppe
    Alessi, Joao Victor
    Pecci, Federica
    Di Federico, Alessandro
    Wang, Xinan
    Barrichello, Adriana
    Vaz, Victor
    Pangilinan, Andy
    Haradon, Danielle
    Elinton, Lee
    Nishino, Mizuki
    Rodig, Scott
    Sholl, Lynette
    Awad, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A553 - A554
  • [3] Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
    Ricciuti, Biagio
    Alessi, Joao Victor Machado
    Li, Yvonne Y.
    Vaz, Victor R.
    Pecci, Federica
    Lamberti, Giuseppe
    de Castro Barrichello, Adriana Paula
    Gupta, Hersh
    Nishino, Mizuki
    Cherniack, Andrew D.
    Sholl, Lynette M.
    Rodig, Scott J.
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Impact of age on outcomes with PD-(L)1 blockade in patients (Pts) with non-small cell lung cancer (NSCLC).
    Lichtenstein, Morgan
    Nipp, Ryan David
    Goodwin, Kelly
    Anderson, Danyon
    Newcomb, Richard
    Gainor, Justin F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts)
    Ferrara, R.
    Naigeon, M.
    Auclin, E.
    Duchemann, B.
    Cassard, L.
    Medhi, J. J.
    Boselli, L.
    Grivel, J.
    Desnoyer, A.
    Mezquita, L.
    Hendriks, L.
    Planchard, D.
    Caramella, C.
    Remon-Masip, J.
    Sangaletti, S.
    Garassino, M. C.
    Besse, B.
    Chaput, N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO)
    Ferrara, R.
    Naigeon, M.
    Auclin, E.
    Duchemann, B.
    Cassard, L.
    Medhi, J.
    Boselli, L.
    Grivel, J.
    Desnoyer, A.
    Mezquita, L.
    Aboubakar, F.
    Hendriks, L.
    Planchard, D.
    Caramella, C.
    Remon, J.
    Ngocamus, M.
    Nicotra, C.
    Besse, B.
    Chaput, N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small cell lung cancer
    Ricciuti, Biagio
    Lamberti, Giuseppe
    Puchala, Sreekar
    Mahadevan, Navin
    Alessi, Joao
    Wang, Xinan
    Li, Yvonne
    Pecci, Federica
    Di Federico, Alessandro
    Gandhi, Malini
    Barrichello, Adriana
    Vaz, Victor
    Pangilinan, Andy
    Haradon, Danielle
    Lee, Elinton
    Gupta, Hersh
    Nishino, Mizuki
    Cherniack, Andrew
    Rodig, Scott
    Sholl, Lynette
    Umeton, Renato
    Awad, Mark M.
    CANCER RESEARCH, 2023, 83 (07)
  • [8] MYC expression correlates with PD-L1 expression and related poor clinical outcome in non-small cell lung cancer
    Kim, Eun Young
    Kim, Arum
    Kim, Se Kyu
    Chang, Yoon Soo
    CANCER RESEARCH, 2017, 77
  • [9] Multifactorial Model to Predict Response to PD-(L)1 Blockade in Patients with High PD-L1 Metastatic Non-Small Cell Lung Cancer
    Arbour, K.
    Oprescu, M.
    Hakim, J.
    Rizvi, H.
    Leiserson, M.
    Ginsburg, M.
    Plodkowski, A.
    Sauter, J.
    Preeshagul, I.
    Gillett, S.
    Rosenfield, P.
    Mackey, L.
    Dudik, M.
    Hellmann, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S290 - S290
  • [10] Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer
    Zhang, Xuchen
    Zhang, Hefeng
    Hou, Feng
    Fang, Tao
    Zhang, Chuantao
    Wang, Huiyun
    Song, Shanai
    Lan, Hongwei
    Wang, Yongjie
    Hou, Helei
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
12345